Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome|
|Citation:||Cochrane Database of Systematic Reviews, 2003; 2003(2):www 1-www 79|
|Publisher:||Update Software Ltd|
|J.M. Lord, I.H.K. Flight and R.J. Norman|
|Abstract:||Polycystic ovary syndrome (PCOS) is characterised by anovulation, hyperandrogenaemia and insulin resistance. Hyperinsulinaemia is known to be associated with an increase in cardiovascular risk and the development of diabetes mellitus. If insulin sensitising agents such as metformin are effective in treating features of PCOS, then they could have wider health benefits than just treating the symptoms of the syndrome.|
Polycystic Ovary Syndrome
Randomized Controlled Trials as Topic
|Description:||Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.|
|Appears in Collections:||Aurora harvest 4|
Obstetrics and Gynaecology publications
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.